Dynavax Technologies Corp
DVAX15.500USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
242.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Dynavax Technologies Corp Unternehmen
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Dynavax Technologies Corp Informationen
BörsenkürzelDVAX
Name des UnternehmensDynavax Technologies Corp
IPO-datumFeb 19, 2004
CEOSpencer (Ryan)
Anzahl der mitarbeiter405
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 19
Addresse2100 Powell Street
StadtEMERYVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94608
Telefon15108485100
Websitehttps://www.dynavax.com/
BörsenkürzelDVAX
IPO-datumFeb 19, 2004
CEOSpencer (Ryan)
Führungskräfte von Dynavax Technologies Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
1.44K
--
Dr. Francis R. Cano, Ph.D.
Dr. Francis R. Cano, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
--
-100.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
Nach RegionUSD
Name
Umsatz
Anteil
US
94.69M
99.81%
Non-US
183.00K
0.19%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
Aktionärsstatistik
Aktualisiert: Sat, Feb 21
Aktualisiert: Sat, Feb 21
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.02%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
6.30%
Chicago Capital, LLC
3.05%
Renaissance Technologies LLC
2.94%
Andere
67.65%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.02%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
6.30%
Chicago Capital, LLC
3.05%
Renaissance Technologies LLC
2.94%
Andere
67.65%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.46%
Investment Advisor/Hedge Fund
25.07%
Hedge Fund
16.66%
Research Firm
6.13%
Pension Fund
0.97%
Bank and Trust
0.45%
Individual Investor
0.31%
Private Equity
0.04%
Insurance Company
0.03%
Andere
13.88%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
546
115.83M
109.38%
+66.95K
2025Q3
565
115.78M
113.44%
+813.17K
2025Q2
563
116.95M
120.36%
-13.51M
2025Q1
558
131.20M
118.77%
-16.39M
2024Q4
550
133.28M
116.08%
-4.50M
2024Q3
545
132.56M
115.53%
-2.40M
2024Q2
531
134.71M
114.10%
-1.03M
2024Q1
527
135.87M
107.19%
-4.14M
2023Q4
514
128.04M
106.45%
-253.89K
2023Q3
500
128.23M
106.72%
-886.82K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
14.70M
12.93%
-1.10M
-6.96%
Sep 30, 2025
The Vanguard Group, Inc.
8.08M
7.11%
-327.20K
-3.89%
Sep 30, 2025
State Street Investment Management (US)
6.29M
5.53%
-110.47K
-1.73%
Sep 30, 2025
Chicago Capital, LLC
4.31M
3.79%
-919.11K
-17.58%
Sep 30, 2025
Renaissance Technologies LLC
3.14M
2.76%
+252.02K
+8.73%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.57M
3.14%
-77.23K
-2.12%
Sep 30, 2025
Two Sigma Investments, LP
3.01M
2.65%
-784.25K
-20.67%
Sep 30, 2025
Marshall Wace LLP
2.04M
1.79%
+221.07K
+12.18%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.53M
2.23%
-158.37K
-5.89%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Biotechnology & Genome ETF
2.91%
Virtus LifeSci Biotech Products ETF
1.58%
ETC 6 Meridian Small Cap Equity ETF
1.21%
Invesco S&P SmallCap Health Care ETF
0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.42%
State Street SPDR S&P Biotech ETF
0.41%
Themes US Small Cap Cash Flow Champions ETF
0.35%
Royce Quant Small-Cap Quality Value ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil2.91%
Virtus LifeSci Biotech Products ETF
Anteil1.58%
ETC 6 Meridian Small Cap Equity ETF
Anteil1.21%
Invesco S&P SmallCap Health Care ETF
Anteil0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
Anteil0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil0.42%
State Street SPDR S&P Biotech ETF
Anteil0.41%
Themes US Small Cap Cash Flow Champions ETF
Anteil0.35%
Royce Quant Small-Cap Quality Value ETF
Anteil0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
